View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
April 27, 2011

GlaxoSmithKline Profits Rise Despite Sales Slump

UK-based pharmaceutical major GlaxoSmithKline has seen its profits increase 14% despite decreasing product sales, with profits of £1.525bn reported in the first quarter. GlaxoSmithKline said that its major cost-cutting programme and asset disposals had helped to offsets sales of £6.5

By cms admin

UK-based pharmaceutical major GlaxoSmithKline has seen its profits increase 14% despite decreasing product sales, with profits of £1.525bn reported in the first quarter.

GlaxoSmithKline said that its major cost-cutting programme and asset disposals had helped to offsets sales of £6.585bn, equating to a 10% drop in comparison to the corresponding quarter of last year.

The company said that the 10% decrease reflected a £1bn reduction in sales, relating to pandemic products and the EU medicines regulator decision to withdraw diabetes medication Avandia from the shelves over heart fears.

GlaxoSmithKline has since made a number of cost-saving measures, cutting thousands of jobs worldwide, in an attempt to alleviate the impact of the decision.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU